Context Therapeutics® to Participate in Two April 2022 Investor Conferences
April 06, 2022 07:30 ET
|
Context Therapeutics Inc.
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy...
Context Therapeutics® Reports Full Year 2021 Operating and Financial Results
March 23, 2022 16:01 ET
|
Context Therapeutics Inc.
Investor R&D event on April 13th to highlight new preclinical data to be presented at AACR Annual Meeting Strong cash position following $28.75M initial public offering and $31.25M private...
Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 08, 2022 18:12 ET
|
Context Therapeutics Inc.
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy...
Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum
February 22, 2022 07:30 ET
|
Context Therapeutics Inc.
PHILADELPHIA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy...
Context Therapeutics® Strengthens Research & Development Team
January 05, 2022 16:01 ET
|
Context Therapeutics Inc.
PHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy...
Context Therapeutics® to Participate in Two January 2022 Investor Conferences
January 04, 2022 07:30 ET
|
Context Therapeutics Inc.
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy...
Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium
December 09, 2021 18:00 ET
|
Context Therapeutics Inc.
Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical trials in progress also presented ...
Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement
December 06, 2021 16:45 ET
|
Context Therapeutics Inc.
PHILADELPHIA, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women’s oncology company developing small molecule and...
Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results
December 02, 2021 16:01 ET
|
Context Therapeutics Inc.
Entered into $31.25 million Private Placement Agreement Completed Initial Public Offering of Common Stock and Raised $28.75 million in Gross Proceeds Dosed First Patient in Phase 2 ER+, PR+, HER2-...
Context Therapeutics Inc. Announces $31.25 Million Private Placement
December 01, 2021 18:30 ET
|
Context Therapeutics LLC
PHILADELPHIA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women’s oncology company developing small molecule and...